Holen Sie sich die Stockscreener-App
50.44
0.48%
0.24
Vorhandelsmarkt:
50.66
0.22
+0.44%
Schlusskurs vom Vortag:
$50.20
Offen:
$50.2
24-Stunden-Volumen:
3.27M
Relative Volume:
0.98
Marktkapitalisierung:
$22.41B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
28.33
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+1.82%
1M Leistung:
+3.85%
6M Leistung:
+24.79%
1J Leistung:
+52.85%
1-Tages-Spanne:
$50.06
$50.82
1-Wochen-Bereich:
$49.11
$50.82
52-Wochen-Spanne:
$31.97
$50.82
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
50.44 | 22.41B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma earnings in focus as deal activity accelerates By Investing.com - Investing.com South Africa
Royalty Pharma to Announce Q1 Earnings on May 6 - Intellectia AI
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighStill a Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at 50.49 USD - Investing.com
MSN Money - MSN
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Bought by UBS Group AG - MarketBeat
Hussman Strategic Advisors Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lifted by CM Management LLC - MarketBeat
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX) - Sahm
Pictet Asset Management Holding SA Sells 62,539 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock - Investing.com Canada
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock By Investing.com - Investing.com South Africa
Royalty Pharma Insider Sold Shares Worth $1,731,840, According to a Recent SEC Filing - marketscreener.com
Royalty Pharma (RPRX) CFO sells 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Hits New 52-Week High of $50.24 - Markets Mojo
Royalty Pharma Plc Experiences Revision in Its Stock Evaluation Amid Strong Performance - Markets Mojo
Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Mitsubishi UFJ Trust & Banking Corp Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits 52-week high at $50.24 By Investing.com - Investing.com South Africa
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Affiliate sales disclosed for RPRX (NASDAQ: RPRX) in Form 144 filing - Stock Titan
Royalty Pharma prices $2B senior unsecured notes - MSN
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $50.24 - Investing.com
Teacher Retirement System of Texas Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma declares $0.235 dividend - MSN
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma plc (RPRX) Stock Analysis: Harnessing Biopharma Royalties with a 6% Upside Potential - DirectorsTalk Interviews
A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum - Yahoo Finance
RPRX.O - Reuters
Zurcher Kantonalbank Zurich Cantonalbank Acquires 219,479 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Torray Investment Partners LLC - MarketBeat
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - Stock Traders Daily
3 Unpopular Stocks We’re Skeptical Of - Yahoo Finance
Ruffer LLP Has $3.50 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation - The Manila Times
A new $1 million prize will honor scientists who turn discoveries into drugs - Stock Titan
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS raises Royalty Pharma stock price target on biopharma catalysts By Investing.com - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $57 at UBS - StreetInsider
Royalty Pharma Approves Dividend and Expands J&J Research Funding - HarianBasis.co
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.88%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):